BAX/BAK are restrained by the anti-apoptotic BCL-2, and BCL-2 inhibition by venetoclax, which consequently promotes BAX/BAK-mediated apoptosis, has already advanced AML treatments24. This evidence concerns the gene BCL2 and acute myeloid leukemia.